Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$282,305,533
-$12,788,067 QoQ
Shares Held
1,801,337
-6.8% QoQ
Ownership
0.095%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#21
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 2%
Shared 0%
None 98%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026RAYMOND JAMES FINANCIAL INC holds $10,536,270,733 across 17 Drug Manufacturers - General names. NVS ranks #9 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
10,410,159 | $2,619,612,407 | |
| 2 | JNJ |
Johnson & Johnson
|
10,114,310 | $2,568,731,308 | |
| 3 | LLY |
ELI LILLY & Co
|
1,713,850 | $2,055,643,274 | |
| 4 | MRK |
Merck & Co., Inc.
|
6,236,773 | $801,425,329 | |
| 5 | AMGN |
Amgen Inc
|
1,602,419 | $580,267,967 | |
| 6 | AZN |
Astrazeneca PLC
|
2,409,624 | $456,912,900 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
2,436,019 | $307,766,638 | |
| 8 | PFE |
Pfizer Inc
|
11,942,054 | $287,564,657 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $282,305,533 | 1,801,337 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $295,093,600 | 1,931,873 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $254,453,558 | 1,845,605 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $211,361,831 | 1,648,174 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $112,214,266 | 927,314 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $99,926,657 | 896,364 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $88,339,183 | 907,812 | Shares | Defined | 2025-04-23 | |
| No filing history on record for this holder in this stock. | ||||||